Recently, a clinical trial enrollment was stopped ahead of schedule because of safety concerns. The trial's early findings indicated that the risk of severe lower respiratory tract disease in infants caused by the respiratory syncytial virus (RSV) was lower with the maternal vaccine candidate than with the placebo.
However, the risk of preterm birth was found to be higher with the candidate vaccine.
Read More
